This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad's Prolaris(R) Test Guides Treatment Decisions For Men With Prostate Cancer

SALT LAKE CITY, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from four clinical studies with Prolaris at the 14 th Annual Meeting of the Society for Urologic Oncology (SUO) in Bethesda, Md. Prolaris is a prognostic test that accurately predicts cancer-specific disease progression and mortality based on an analysis of 46 cell cycle progression genes. The Prolaris score has been demonstrated to be a stronger predictor of prostate cancer recurrence and cancer-specific death than clinical parameters such as Gleason score and PSA. 

In addition to compelling data on the clinical utility of Prolaris in changing treatment plans for men with prostate cancer, the Company will present data from two new clinical studies on the Prolaris test. These studies further demonstrate the ability of the Prolaris test to accurately stratify a prostate cancer patient's risk of having an aggressive form of the disease. Prolaris has now been validated in 11 clinical studies in approximately 5,000 patients with prostate cancer. Another new study in renal cell carcinoma also will be presented at the SUO meeting, demonstrating that Myriad's cell cycle progression gene panel predicts metastatic progression in patients with this deadly cancer.

"A major challenge for physicians treating men with prostate cancer is knowing whether a prostatectomy or other type of treatment is necessary, or if active surveillance is appropriate," said Michael Brawer, M.D. vice president of Medical Affairs at Myriad Genetic Laboratories. "Our data demonstrate the utility of Prolaris in helping physicians determine the most appropriate and effective treatment for each individual patient based on the aggressiveness of their cancer."

Clinical Utility of Cell Cycle Progression Genes in Facilitating Prostate Cancer Treatment Decisions. [Shore et al., Poster Session II: Dec. 6, 2013, 4:30 p.m. ET]

The prostate biopsy research study evaluated Prolaris' potential clinical utility in guiding the treatment decision for patients diagnosed with prostate cancer. Participating physicians were asked to assess the value of the Prolaris score and questionnaires were completed for 294 evaluable patients with localized prostate cancer.  Physicians indicated that 55 percent of tests generated a mortality risk score that was either higher or lower than what they expected.  Physicians also indicated that 32 percent of test results would lead to a definite or possible change in treatment plan, with the net effect of shifting patients from more aggressive to more conservative treatment. These data strongly suggest that the Prolaris test can help physicians determine the aggressiveness of prostate cancer and tailor treatment plans for individual patients. A second large prospective clinical utility study called PROCEDE 500 also is underway. An interim analysis of that study showed that physicians would change actual treatment selection in 65 percent of cases after they reviewed the results of the Prolaris test with their patients. Data from PROCEDE 500 will be presented at the ASCO Genitourinary Cancers Symposium in San Francisco on Jan. 30, 2014.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,949.59 -85.34 -0.47%
S&P 500 2,097.29 -3.11 -0.15%
NASDAQ 5,014.1020 +19.50 0.39%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs